Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16076280 | 0.93 | TDP1 (0.47) | MEN1KMT2AALDH1A1LMNAKDM4E | |
| SCHEMBL19268642 | 0.93 | TDP1 (0.47) | MEN1KMT2AALDH1A1LMNAKDM4E | |
| SCHEMBL29389686 | 0.90 | MEN1 (0.50) | MEN1KMT2AALDH1A1LMNAKDM4E | |
| SCHEMBL8390812 | 0.84 | SIGMAR1 (0.46) | KMT2AALDH1A1KDM4ETDP1 | |
| SCHEMBL19274143 | 0.84 | ALDH1A1 (0.39) | MEN1KMT2AALDH1A1LMNAKDM4E | |
| SCHEMBL25891056 | 0.84 | HSD17B10 (0.48) | MEN1KMT2AALDH1A1LMNAKDM4E | |
| SCHEMBL17532577 | 0.84 | ALDH1A1 (0.39) | MEN1KMT2AALDH1A1LMNAKDM4E | |
| SCHEMBL12866025 | 0.84 | HSD17B10 (0.48) | MEN1KMT2AALDH1A1LMNAKDM4E | |
| SCHEMBL12233164 | 0.83 | — | — | |
| SCHEMBL8809555 | 0.83 | GAA (0.48) | MEN1KMT2AALDH1A1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015959-A1 | HETEROCYCLIC COMPOUNDS AS AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015959-A1 | HETEROCYCLIC COMPOUNDS AS AUTOTAXIN INHIBITORS | ENPP2, HAX1, MTX1 | MEN1 176/4885KMT2A 1968/4885ALDH1A1 4564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.